HK Stock Market Move | YIDU TECH (02158) rises more than 17%, AI expected to reshape pharmaceutical paradigm, Company has integrated self-developed "AI Medical Brain" YiduCore.

The concept of AI pharmaceuticals remains active, with YIDU TECH (02158) rising more than 17% in early trading, with a total increase of over 40% in the past week's trading days. As of the time of writing, it has risen by 17.11% to HK$6.97, with a transaction volume of HK$2.08 billion. In terms of news, it was reported recently that YIDU TECH has integrated the DeepSeek artificial intelligence model into its independently developed "AI Medical Brain" YiduCore, which will further promote the large-scale application and innovative practices of AI technology in the medical and health industry. CITIC SEC believes that AI pharmaceuticals are continuously empowering traditional drug discovery processes such as target discovery and validation, candidate compound discovery, etc. under the methods of deep learning and reinforcement learning, playing a key role in virtual screening and de novo molecule generation. In the short term, the number of AI pharmaceutical pipelines and the market size are showing rapid growth trends, and a group of domestic and foreign AI pharmaceutical companies have gradually emerged with the AI+Biotech/SaaS/CRO model, accelerating the new drug development process through their own platforms. In the medium to long term, Recursion is starting to break away from the traditional drug discovery model by combining image recognition with epigenetic screening, indicating that AI is poised to reshape the pharmaceutical paradigm. At the same time, AI drugs show superior performance in the early clinical stages, with advantages in the success rates of Phase I and Phase II clinical trials compared to traditional drug discovery. With the gradual acceleration of the pre-clinical development process and paradigm shift, combined with the gradual coverage of AI in the clinical stages, AI is expected to overcome the barriers between in vivo and in vitro data, truly realizing the vast expanse of drug discovery.